Pinz Capital Management’s Heron Therapeutics HRTX Stock Holding History

Pinz Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$311K	Buy	+73,765	New	+$289K	0.56%	56

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Pinz Capital Management's HRTX Position: Q3 2022 in Review

Pinz Capital Management opened a new position in Heron Therapeutics (HRTX) in Q3 2022: 73,765 shares worth $311K. The stake represents 0.56% of the portfolio and ranks #56 among its holdings.

186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

Pinz Capital Management held 73,765 shares of Heron Therapeutics worth $311K as of Q3 2022.
Heron Therapeutics was a new Pinz Capital Management position in Q3 2022.
Heron Therapeutics made up 0.56% of Pinz Capital Management's portfolio in Q3 2022, its #56 holding.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.